1. Impact of eGFR rate on 1-year all-cause mortality in patients with stable coronary artery disease.
- Author
-
De Luca, Leonardo, Cappadona, Francesca, Temporelli, Pier Luigi, Gonzini, Lucio, Ledda, Antonietta, Raisaro, Arturo, Viazzi, Francesca, Gabrielli, Domenico, Colivicchi, Furio, Gulizia, Michele Massimo, and Pontremoli, Roberto
- Subjects
- *
CORONARY artery disease , *MORTALITY , *EPIDERMAL growth factor receptors , *DIASTOLIC blood pressure , *GLOMERULAR filtration rate - Abstract
• The prognostic impact of different degree of estimated glomerular filtration rate (eGFR) reduction in patients with stable coronary artery disease (CAD) is poorly studied. • We studied 4,130 patients with stable CAD recruited in a prospective, observational, nationwide study in Italy. • Baseline management and all-cause 1-year mortality were evaluated according to groups of eGFR (<30; 30-59; 60-89; ≥90 ml/min/1.73 m2). • Progressively lower eGFR significantly correlated with all-cause 1-year mortality Coronary artery disease (CAD) is a leading cause of mortality and is often complicated by chronic kidney disease. We sought to investigate the prevalence of different degree of estimated glomerular filtration rate (eGFR) reduction, the clinical and bio-humoral correlates, its relationship with therapeutic management, and its predictive role on 1-year all-cause mortality, in patients with stable CAD. We studied 4,130 patients with stable CAD recruited in a prospective, observational, nationwide study (START, STable coronary Artery diseases RegisTry) in Italy. Baseline clinical characteristics, pharmacological treatment, and all-cause 1-year mortality were evaluated according to groups of eGFR (<30; 30-59; 60-89; ≥90 ml/min/1.73 m2) at baseline. The presence and the degree of chronic kidney disease entailed an unfavorable risk profile, since it was gradually associated with more comorbidities. Furthermore, progressively lower eGFR values were associated to lower diastolic blood pressure and hemoglobin values. As eGFR lowers, optimal medical treatment and its persistence overtime is reduced. Multivariate analysis showed that progressively lower eGFR significantly correlated with all-cause 1-year mortality [hazard ratio (HR): 1.02; 95% confidence intervals (CI): 1.01-1-03; p = 0.0001]. Low eGFR is associated with an increasing risk of all-cause mortality in patients with stable CAD. Chronic kidney disease may hamper the optimization of treatment limiting the use of drugs which may favorably impact cardiovascular and renal outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF